Laurus Labs Ltd
Company Profile
Business description
Laurus Labs Ltd is a pharmaceutical company based in India. It provides active pharmaceutical ingredients (API) including intermediates, Generic Finished dosage forms (FDF), and Contract Research services. The entity develops APIs and intermediates for select, high-growth antiretrovirals, Hepatitis C and Oncology. It also manufactures APIs in other therapeutic areas, such as anti-asthma, ophthalmology, anti-diabetics, cardiovascular, and proton pump inhibitors, among others. The company has its business presence in India and Outside India of which it derives a majority of revenue from Outside India. It generates revenue from the sale of API, Intermediates and Formulations, Contract research services, and others.
Contact
Road No. 7, Banjara Hills
2nd Floor, Serene Chambers
HyderabadTG500034
INDT: +91 4039804333
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2027
Employees
12,467
Stocks News & Analysis
stocks
US utilities stocks keep rallying as investors bet on power demand growth
stocks
What did Morningstar subscribers buy and sell during March?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,183.40 | 23.00 | -0.25% |
| CAC 40 | 8,235.98 | 23.62 | -0.29% |
| DAX 40 | 23,742.44 | 61.51 | -0.26% |
| Dow JONES (US) | 48,218.25 | 301.68 | 0.63% |
| FTSE 100 | 10,582.96 | 17.57 | -0.17% |
| HKSE | 25,894.13 | 233.28 | 0.91% |
| NASDAQ | 23,183.74 | 280.84 | 1.23% |
| Nikkei 225 | 57,943.93 | 1,441.16 | 2.55% |
| NZX 50 Index | 13,047.86 | 27.68 | 0.21% |
| S&P 500 | 6,886.24 | 69.35 | 1.02% |
| S&P/ASX 200 | 8,988.40 | 25.60 | -0.28% |
| SSE Composite Index | 4,005.54 | 16.98 | 0.43% |